DexCom, Inc. vs iShares MSCI Malaysia ETF — how do they compare? DexCom, Inc. trades at $89.06 (market cap $33.79B), while iShares MSCI Malaysia ETF trades at $28.28. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | EWM | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $30.42 |
52-Week Low | $54.84 | $24.73 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →